Collectively, our studies support that PAK1 mediates BMM-induced drug resistance via ERK1/2 signaling pathway in AML, which provides insights for the molecular mechanism of BMM-mediated treatment resistance and targeted or combined treatment. Here, MAPK3 is linked to acute myeloid leukemia.